Search

Your search keyword '"Metra, Marco"' showing total 38 results
Start Over Author "Metra, Marco" Journal heart failure reviews
38 results on '"Metra, Marco"'

4. Creatine deficiency and heart failure

Author

Del Franco, Annamaria, Ambrosio, Giuseppe, Baroncelli, Laura, Pizzorusso, Tommaso, Barison, Andrea, Olivotto, Iacopo, Recchia, Fabio A., Lombardi, Carlo M., Metra, Marco, Ferrari Chen, Yu F., Passino, Claudio, Emdin, Michele, and Vergaro, Giuseppe

Published
2022
Full Text
View/download PDF

8. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions

Author

Gheorghiade, Mihai, Vaduganathan, Muthiah, Greene, Stephen J, Mentz, Robert J, Adams, Kirkwood F, Anker, Stefan D, Arnold, Malcolm, Baschiera, Fabio, Cleland, John GF, Cotter, Gadi, Fonarow, Gregg C, Giordano, Christopher, Metra, Marco, Misselwitz, Frank, Mühlhofer, Eva, Nodari, Savina, Frank Peacock, W, Pieske, Burkert M, Sabbah, Hani N, Sato, Naoki, Shah, Monica R, Stockbridge, Norman L, Teerlink, John R, van Veldhuisen, Dirk J, Zalewski, Andrew, Zannad, Faiez, and Butler, Javed

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Cardiovascular, Heart Disease, Clinical Trials and Supportive Activities, Clinical Trials as Topic, Heart Failure, Hospitalization, Humans, Inpatients, Patient Selection, Research Design, Therapies, Investigational, United States, Heart failure, Site selection, Clinical trials, FDA, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

There are over 1 million hospitalizations for heart failure (HF) annually in the United States alone, and a similar number has been reported in Europe. Recent clinical trials investigating novel therapies in patients with hospitalized HF (HHF) have been negative, and the post-discharge event rate remains unacceptably high. The lack of success with HHF trials stem from problems with understanding the study drug, matching the drug to the appropriate HF subgroup, and study execution. Related to the concept of study execution is the importance of including appropriate study sites in HHF trials. Often overlooked issues include consideration of the geographic region and the number of patients enrolled at each study center. Marked differences in baseline patient co-morbidities, serum biomarkers, treatment utilization and outcomes have been demonstrated across geographic regions. Furthermore, patients from sites with low recruitment may have worse outcomes compared to sites with higher enrollment patterns. Consequently, sites with poor trial enrollment may influence key patient end points and likely do not justify the costs of site training and maintenance. Accordingly, there is an unmet need to develop strategies to identify the right study sites that have acceptable patient quantity and quality. Potential approaches include, but are not limited to, establishing a pre-trial registry, developing site performance metrics, identifying a local regionally involved leader and bolstering recruitment incentives. This manuscript summarizes the roundtable discussion hosted by the Food and Drug Administration between members of academia, the National Institutes of Health, industry partners, contract research organizations and academic research organizations on the importance of selecting optimal sites for successful trials in HHF.

Published
2014

9. Relaxin, a pleiotropic vasodilator for the treatment of heart failure

Author

Teichman, Sam L, Unemori, Elaine, Dschietzig, Thomas, Conrad, Kirk, Voors, Adriaan A, Teerlink, John R, Felker, G Michael, Metra, Marco, and Cotter, Gad

Subjects
Medical Physiology, Biomedical and Clinical Sciences, Heart Disease, Cardiovascular, Clinical Research, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Animals, Female, Heart Failure, Humans, Kidney, Pregnancy, Regional Blood Flow, Relaxin, Vasodilation, Vasodilator Agents, Acute heart failure, Vasodilator, Hemodynamic, Renovascular, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

Relaxin is a naturally occurring peptide hormone that plays a central role in the hemodynamic and renovascular adaptive changes that occur during pregnancy. Triggering similar changes could potentially be beneficial in the treatment of patients with heart failure. The effects of relaxin include the production of nitric oxide, inhibition of endothelin, inhibition of angiotensin II, production of VEGF, and production of matrix metalloproteinases. These effects lead to systemic and renal vasodilation, increased arterial compliance, and other vascular changes. The recognition of this has led to the study of relaxin for the treatment of heart failure. An initial pilot study has shown favorable hemodynamic effects in patients with heart failure, including reduction in ventricular filling pressures and increased cardiac output. The ongoing RELAX-AHF clinical program is designed to evaluate the effects of relaxin on the symptoms and outcomes in a large group of patients admitted to hospital for acute heart failure. This review will summarize both the biology of relaxin and the data supporting its potential efficacy in human heart failure.

Published
2009

10. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond

Author

Teerlink, John R., Metra, Marco, Zacà, Valerio, Sabbah, Hani N., Cotter, Gadi, Gheorghiade, Mihai, and Cas, Livio Dei

Subjects
Medicine & Public Health, Cardiology, Acute heart failure, Advanced chronic heart failure, Inotropic agents, Prognosis, Istaroxime, Omecamtiv mecarbil
Abstract

Treatment with inotropic agents is one of the most controversial topics in heart failure. Initial enthusiasm, based on strong pathophysiological rationale and apparent empirical efficacy, has been progressively limited by results of controlled trials and registries showing poorer outcomes of the patients on inotropic therapy. The use of these agents remains, however, potentially indicated in a significant proportion of patients with low cardiac output, peripheral hypoperfusion and end-organ dysfunction caused by heart failure. Limitations of inotropic therapy seem to be mainly related to their mechanisms of action entailing arrhythmogenesis, peripheral vasodilation, myocardial ischemia and damage, and possibly due to their use in patients without a clear indication, rather than to the general principle of inotropic therapy itself. This review will discuss the characteristics of the patients with a potential indication for inotropic therapy, the main data from registries and controlled trials, the mechanism of the untoward effects of these agents on outcomes and, lastly, perspectives with new agents with novel mechanisms of action.

Published
2009

11. Redefining biomarkers in heart failure

Author

Correale, Michele, Monaco, Ilenia, Brunetti, Natale Daniele, Di Biase, Matteo, Metra, Marco, Nodari, Savina, Butler, Javed, Gheorghiade, Mihi, and On behalf of Master Program Students on Drug Development for Heart Failure

Published
2018
Full Text
View/download PDF

15. Creatine deficiency and heart failure

Author

Del Franco, Annamaria, primary, Ambrosio, Giuseppe, additional, Baroncelli, Laura, additional, Pizzorusso, Tommaso, additional, Barison, Andrea, additional, Olivotto, Iacopo, additional, Recchia, Fabio A., additional, Lombardi, Carlo M., additional, Metra, Marco, additional, Ferrari Chen, Yu F., additional, Passino, Claudio, additional, Emdin, Michele, additional, and Vergaro, Giuseppe, additional

Published
2021
Full Text
View/download PDF

17. Soluble guanylate cyclase: a potential therapeutic target for heart failure

Author

Gheorghiade, Mihai, Marti, Catherine N., Sabbah, Hani N., Roessig, Lothar, Greene, Stephen J., Böhm, Michael, Burnett, John C., Campia, Umberto, Cleland, John G. F., Collins, Sean P., Fonarow, Gregg C., Levy, Phillip D., Metra, Marco, Pitt, Bertram, Ponikowski, Piotr, Sato, Naoki, Voors, Adriaan A., Stasch, Johannes-Peter, and Butler, Javed

Published
2013
Full Text
View/download PDF

18. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure

Author

Gheorghiade, Mihai, Vaduganathan, Muthiah, Ambrosy, Andrew, Böhm, Michael, Campia, Umberto, Cleland, John G. F., Fedele, Francesco, Fonarow, Gregg C., Maggioni, Aldo P., Mebazaa, Alexandre, Mehra, Mandeep, Metra, Marco, Nodari, Savina, Pang, Peter S., Ponikowski, Piotr, Sabbah, Hani N., Komajda, Michel, and Butler, Javed

Published
2013
Full Text
View/download PDF

19. Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?

Author

Correale, Michele, primary, Petroni, Renata, additional, Coiro, Stefano, additional, Antohi, Elena-Laura, additional, Monitillo, Francesco, additional, Leone, Marta, additional, Triggiani, Marco, additional, Ishihara, Shiro, additional, Dungen, Hans-Dirk, additional, Sarwar, Chaudhry M. S., additional, Memo, Maurizio, additional, Sabbah, Hani N., additional, Metra, Marco, additional, Butler, Javed, additional, and Nodari, Savina, additional

Published
2021
Full Text
View/download PDF

30. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions

Author

Gheorghiade, Mihai, primary, Vaduganathan, Muthiah, additional, Greene, Stephen J., additional, Mentz, Robert J., additional, Adams, Kirkwood F., additional, Anker, Stefan D., additional, Arnold, Malcolm, additional, Baschiera, Fabio, additional, Cleland, John G. F., additional, Cotter, Gadi, additional, Fonarow, Gregg C., additional, Giordano, Christopher, additional, Metra, Marco, additional, Misselwitz, Frank, additional, Mühlhofer, Eva, additional, Nodari, Savina, additional, Frank Peacock, W., additional, Pieske, Burkert M., additional, Sabbah, Hani N., additional, Sato, Naoki, additional, Shah, Monica R., additional, Stockbridge, Norman L., additional, Teerlink, John R., additional, van Veldhuisen, Dirk J., additional, Zalewski, Andrew, additional, Zannad, Faiez, additional, and Butler, Javed, additional

Published
2012
Full Text
View/download PDF

31. Anticoagulation in heart failure: current status and future direction

Author

Gheorghiade, Mihai, primary, Vaduganathan, Muthiah, additional, Fonarow, Gregg C., additional, Greene, Stephen J., additional, Greenberg, Barry H., additional, Liu, Peter P., additional, Massie, Barry M., additional, Mehra, Mandeep R., additional, Metra, Marco, additional, Zannad, Faiez, additional, Cleland, John G. F., additional, van Veldhuisen, Dirk J., additional, Shah, Ami N., additional, and Butler, Javed, additional

Published
2012
Full Text
View/download PDF

32. Soluble guanylate cyclase: a potential therapeutic target for heart failure

Author

Gheorghiade, Mihai, primary, Marti, Catherine N., additional, Sabbah, Hani N., additional, Roessig, Lothar, additional, Greene, Stephen J., additional, Böhm, Michael, additional, Burnett, John C., additional, Campia, Umberto, additional, Cleland, John G. F., additional, Collins, Sean P., additional, Fonarow, Gregg C., additional, Levy, Phillip D., additional, Metra, Marco, additional, Pitt, Bertram, additional, Ponikowski, Piotr, additional, Sato, Naoki, additional, Voors, Adriaan A., additional, Stasch, Johannes-Peter, additional, and Butler, Javed, additional

Published
2012
Full Text
View/download PDF

33. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure

Author

Gheorghiade, Mihai, primary, Vaduganathan, Muthiah, additional, Ambrosy, Andrew, additional, Böhm, Michael, additional, Campia, Umberto, additional, Cleland, John G. F., additional, Fedele, Francesco, additional, Fonarow, Gregg C., additional, Maggioni, Aldo P., additional, Mebazaa, Alexandre, additional, Mehra, Mandeep, additional, Metra, Marco, additional, Nodari, Savina, additional, Pang, Peter S., additional, Ponikowski, Piotr, additional, Sabbah, Hani N., additional, Komajda, Michel, additional, and Butler, Javed, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results